Orchard Therapeutics plc (NASDAQ:ORTX) saw an upside of 0.49% on Monday to $2.06 after adding $0.01. The 5-day average trading volume is 1,906,889 shares of the company’s common stock. It has gained $2.16 in the past week. An average of 1,368,267 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 909,687.
ORTX’s 1-month performance is -29.07% or -$0.78 on its low of $2.01 reached on 10/08/21. The company’s shares have touched a 52-week low of $2.01 and high of $9.08, with the stock’s rally to the 52-week high happening on 02/12/21. YTD, ORTX has lost -52.55% or -$2.25. However, the current price is down -77.31%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Feb 05, 248 days have gone by since the last insider trading activity for Orchard Therapeutics plc (ORTX). FMR LLC (See Remark 1) most recently sold 2,045,510 shares at $6.98 per share on Feb 05. This transaction cost the insider $14,277,660.
Orchard Therapeutics plc (ORTX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.55 for the sector.ORTX stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 124.90 while the price-to-book (PB) in the most recent quarter is 0.98.
Orchard Therapeutics plc’s quick ratio for the period ended June 29 was 7.40, with the current ratio over the same period at 7.40 meaning that ORTX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.12, while the total debt to equity was 0.12. In terms of profitability, the gross margin trailing 12 months is 66.70%. The trailing 12-month EBITDA margin is -6786.28%. The firm’s gross profit as reported stood at $1.74 million against revenue of $2.6 million.
For the quarterly period ending June 29 this year, Orchard Therapeutics plc’s cash and short-term investments amounted to $169.39 million against total debt of $61.52 million. Analysts expected ORTX to announce -$0.33 per share in earnings in its latest quarter, but it posted -$0.29, representing a 12.10% surprise. EBITDA for the quarter stood at more than -$35.11 million. ORTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 100.38 million, with total debt at $61.52 million. Shareholders hold equity totaling $125.37 million
Let’s look briefly at Orchard Therapeutics plc (ORTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 27.34% to suggest the stock is trending oversold, with historical volatility in this time period at 41.36%.
The stock’s 5-day moving average is $2.07, reflecting a -1.19% or -$0.02 change from its current price. ORTX is currently trading -28.20% above its 20-day SMA, -61.29% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -27.70% and -54.69% respectively.
Stochastic %K and %D was 7.09% and 5.95% and the average true range (ATR) pointed at 0.13. The RSI (14) points at 30.03%, while the 14-day stochastic is at 9.42% with the period’s ATR at 0.14. The stock’s 9-day MACD Oscillator is pointing at -0.07 and -0.18 on the 14-day charts.
In the most recent analyst report for Orchard Therapeutics plc (NASDAQ: ORTX), JP Morgan downgraded it to a Neutral rating. They previously had an Overweight rating on the stock. Analysts offering their rating for ORTX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ORTX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is ORTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $8.00 and a high of $15.00, with their median price target at $12.00. Looking at these predictions, the average price target given by analysts is for Orchard Therapeutics plc (ORTX) stock is $11.44.